Novo Nordisk Limits US Supply of Weight Loss Drug Wegovy Due to High Demand
Originally Published 2 years ago — by Endpoints News
Novo Nordisk is temporarily restricting the supply of lower doses of its weight loss drug Wegovy to safeguard continuity of care due to high levels of new patients starting its GLP-1 products. Eli Lilly's experimental Alzheimer's drug, donanemab, slowed cognitive and functional decline by 35% over 18 months in a subset of patients with early Alzheimer's disease. Valneva and Pfizer have delayed their Lyme disease vaccine submission to US and European regulators to 2026, pending Phase III success. Teva has issued a recall over several lots of its fentanyl buccal tablets used to treat cancer patients due to a labeling error. Johnson & Johnson's consumer spinout Kenvue will raise $3.8 billion and start trading on the public markets Thursday.